MedCap AB (publ) (MCAP.ST) Stock Price

MedCap AB (publ) Price

OMX·CLOSED
546.00SEK-2.00 (-0.37 %)
Market closed

Over the last 19 years MedCap AB (publ) grew revenue by 18.1% annually, reaching 2.11 B SEK. Earnings per share have grown at 53.7% per year over the last 17 years. For MedCap AB (publ), the net margin of 10.4% is broadly stable versus 10.5% a few years ago. The consensus 12-month price target for MedCap AB (publ) is 633.93 SEK, about 16.1% above where the stock trades today. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 19% above its 52-week low.

MedCap AB (publ) stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of MedCap AB (publ) over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how MedCap AB (publ) stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing MedCap AB (publ)'s price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

MedCap AB (publ) Stock Price History
DateMedCap AB (publ) Price
8/19/2026546.00 SEK
8/17/2026548.00 SEK
8/14/2026551.00 SEK
8/13/2026546.00 SEK
8/12/2026551.00 SEK
8/11/2026551.50 SEK
8/10/2026531.00 SEK
8/7/2026533.00 SEK
8/6/2026528.00 SEK
8/5/2026538.00 SEK
8/4/2026557.50 SEK
7/31/2026548.50 SEK
7/30/2026553.50 SEK
7/29/2026535.00 SEK
7/28/2026547.50 SEK
7/27/2026557.00 SEK
7/24/2026556.50 SEK
7/23/2026569.50 SEK
7/22/2026574.50 SEK
7/21/2026560.00 SEK
7/20/2026498.60 SEK
7/17/2026505.00 SEK
7/16/2026519.50 SEK
7/15/2026505.00 SEK
7/14/2026507.50 SEK
7/13/2026499.40 SEK
7/10/2026500.50 SEK
7/9/2026508.50 SEK
7/8/2026498.00 SEK
7/7/2026515.00 SEK
7/6/2026526.50 SEK
7/3/2026545.00 SEK
7/2/2026546.00 SEK
7/1/2026531.50 SEK
6/30/2026524.50 SEK
6/29/2026514.00 SEK
6/26/2026513.00 SEK
6/25/2026518.00 SEK
6/24/2026502.50 SEK
6/23/2026481.20 SEK
6/22/2026476.00 SEK
6/18/2026471.80 SEK
6/17/2026479.00 SEK
6/16/2026490.60 SEK
6/15/2026499.60 SEK
6/12/2026499.60 SEK
6/11/2026506.00 SEK
6/10/2026511.50 SEK
6/9/2026501.00 SEK
6/8/2026505.00 SEK
6/5/2026517.00 SEK
6/4/2026510.50 SEK
6/3/2026497.20 SEK
6/2/2026515.00 SEK
6/1/2026510.50 SEK
5/29/2026508.00 SEK
5/28/2026541.00 SEK
5/27/2026568.00 SEK
5/26/2026568.00 SEK
5/25/2026564.50 SEK
5/22/2026559.50 SEK
5/21/2026556.00 SEK
5/20/2026553.00 SEK
5/19/2026548.50 SEK
5/18/2026530.50 SEK
5/15/2026540.50 SEK
5/13/2026546.00 SEK
5/12/2026528.00 SEK
5/11/2026529.00 SEK
5/8/2026509.00 SEK
5/7/2026509.00 SEK
5/6/2026490.80 SEK
5/5/2026467.60 SEK
5/4/2026458.00 SEK
4/30/2026479.80 SEK
4/29/2026478.00 SEK
4/28/2026467.40 SEK
4/27/2026478.20 SEK
4/24/2026489.00 SEK
4/23/2026494.20 SEK
4/22/2026506.50 SEK
4/21/2026511.00 SEK
4/20/2026509.00 SEK
4/17/2026516.00 SEK
4/16/2026515.00 SEK
4/15/2026509.00 SEK
4/14/2026504.50 SEK
4/13/2026482.80 SEK
4/10/2026486.80 SEK
4/9/2026480.00 SEK
4/8/2026489.20 SEK
4/7/2026480.20 SEK
4/2/2026480.08 SEK
3/27/2026458.79 SEK
3/26/2026463.27 SEK
3/25/2026461.16 SEK
3/24/2026462.00 SEK
3/23/2026465.43 SEK
3/20/2026461.53 SEK
3/19/2026464.00 SEK
3/17/2026474.33 SEK
3/16/2026465.03 SEK
3/13/2026475.00 SEK
3/12/2026481.50 SEK
3/11/2026481.58 SEK
3/10/2026488.35 SEK
3/9/2026484.44 SEK
3/6/2026495.00 SEK
3/5/2026495.75 SEK
2/26/2026461.50 SEK
2/25/2026469.91 SEK
2/23/2026474.02 SEK
2/20/2026484.50 SEK
2/19/2026478.71 SEK
2/18/2026471.50 SEK
2/17/2026469.00 SEK
2/16/2026477.49 SEK
2/13/2026480.00 SEK
2/12/2026470.50 SEK
2/11/2026496.32 SEK
2/10/2026495.61 SEK
2/9/2026520.81 SEK
2/6/2026542.00 SEK
2/5/2026493.00 SEK
2/4/2026493.00 SEK
2/3/2026491.04 SEK
2/2/2026492.03 SEK
1/30/2026498.00 SEK
1/29/2026511.00 SEK
1/28/2026511.00 SEK
1/27/2026514.33 SEK
1/26/2026514.00 SEK
1/23/2026524.37 SEK
1/22/2026531.00 SEK
1/21/2026520.11 SEK
1/20/2026517.83 SEK
1/19/2026507.50 SEK
1/16/2026525.97 SEK
1/15/2026511.91 SEK
1/14/2026520.61 SEK
1/13/2026540.90 SEK
1/12/2026548.03 SEK
1/9/2026542.42 SEK
1/8/2026549.04 SEK
1/7/2026547.72 SEK
1/5/2026532.45 SEK
1/2/2026533.00 SEK
12/30/2025543.28 SEK
12/29/2025550.00 SEK
12/23/2025552.27 SEK
12/22/2025539.00 SEK
12/19/2025536.33 SEK
12/18/2025520.00 SEK
12/17/2025518.20 SEK
12/16/2025521.58 SEK
12/15/2025529.51 SEK
12/12/2025530.40 SEK
12/11/2025526.53 SEK
12/10/2025528.95 SEK
12/9/2025535.18 SEK
12/8/2025524.36 SEK
12/5/2025534.16 SEK
12/4/2025539.07 SEK
12/3/2025537.50 SEK
12/2/2025547.97 SEK
12/1/2025557.31 SEK
11/28/2025549.07 SEK
11/27/2025556.00 SEK
11/26/2025549.52 SEK
11/25/2025544.90 SEK
11/24/2025538.00 SEK
11/21/2025539.00 SEK
11/20/2025545.00 SEK
11/19/2025535.72 SEK
11/18/2025527.63 SEK
11/17/2025536.16 SEK
11/14/2025537.07 SEK
11/13/2025548.05 SEK
11/12/2025554.02 SEK
11/11/2025547.77 SEK
11/10/2025549.52 SEK
11/7/2025547.26 SEK
11/6/2025547.35 SEK
11/5/2025570.60 SEK
11/4/2025577.93 SEK
11/3/2025595.06 SEK
10/31/2025618.00 SEK
10/30/2025624.53 SEK
10/29/2025623.88 SEK
10/28/2025624.72 SEK
10/27/2025624.31 SEK
10/24/2025605.00 SEK
10/23/2025578.00 SEK
10/22/2025555.61 SEK
10/21/2025554.56 SEK
10/20/2025553.52 SEK
10/17/2025551.78 SEK
10/16/2025553.02 SEK
10/15/2025561.20 SEK
10/14/2025568.97 SEK
10/13/2025572.37 SEK
10/10/2025570.00 SEK
10/9/2025578.09 SEK
10/8/2025581.88 SEK
10/7/2025591.24 SEK
10/6/2025585.35 SEK
10/3/2025573.58 SEK
10/2/2025569.18 SEK
10/1/2025566.79 SEK
9/29/2025565.00 SEK
9/26/2025568.00 SEK
9/25/2025553.00 SEK
9/24/2025571.04 SEK
9/23/2025587.84 SEK
9/22/2025601.80 SEK
9/19/2025608.88 SEK
9/18/2025607.38 SEK
9/17/2025596.33 SEK
9/16/2025599.86 SEK
9/15/2025609.75 SEK
9/12/2025622.89 SEK
9/11/2025621.45 SEK
9/10/2025614.08 SEK
9/9/2025618.98 SEK
9/8/2025614.03 SEK
9/5/2025610.21 SEK
9/4/2025605.08 SEK
9/3/2025615.27 SEK
9/2/2025606.82 SEK
9/1/2025607.03 SEK
8/29/2025614.38 SEK
8/28/2025616.33 SEK
8/27/2025620.15 SEK
8/26/2025642.00 SEK
8/25/2025652.63 SEK
8/22/2025655.18 SEK
8/21/2025640.63 SEK
8/20/2025653.00 SEK
Access this data via the Eulerpool API
Get Free API Key

MedCap AB (publ) Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
1.59 B SEK
227.50 M SEK
172.20 M SEK
Jan 1, 2024
1.81 B SEK
272.30 M SEK
207.40 M SEK
Jan 1, 2025
2.11 B SEK
300.20 M SEK
219.80 M SEK
Jan 1, 2026 (e)
2.40 B SEK
402.58 M SEK
343.66 M SEK
Jan 1, 2027 (e)
2.64 B SEK
442.90 M SEK
392.43 M SEK
Jan 1, 2028 (e)
2.84 B SEK
475.83 M SEK
432.19 M SEK
Jan 1, 2029 (e)
3.19 B SEK
534.78 M SEK
473.17 M SEK
Jan 1, 2030 (e)
3.82 B SEK
641.03 M SEK
0.00 SEK

MedCap AB (publ) Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 20, 2026, 9:23 AM
 
REVENUEB SEK
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB SEK
EBITM SEK
EBIT MARGIN%
NET INCOMEM SEK
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
0.820.850.410.710.760.820.921.111.591.812.112.402.642.843.193.82
-4.234.29-51.7072.516.777.9312.1221.2942.8413.8016.7213.8010.057.4212.3819.89
22.5523.8533.8234.9838.3139.9040.2841.5858.3558.5315.2315.2315.2315.2315.2315.23
0.180.200.140.250.290.330.370.460.931.060.320.370.400.430.490.58
32.00-3.0018.0047.0083.0089.00127.00170.00227.00272.00300.00402.00442.00475.00534.00641.00
3.92-0.354.386.6310.9610.8913.8615.3014.3015.0614.2316.7616.7416.7516.7616.78
19.00–2.00–53.0060.0096.00117.00172.00207.00219.00343.00392.00432.00473.00–
137.50––––13.2160.0021.8847.0120.355.8056.6214.2910.209.49–
13.4013.4013.4013.4513.4514.8014.8014.8114.8714.8615.0015.0015.0015.0015.0015.00
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales MedCap AB (publ) generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue MedCap AB (publ) retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare MedCap AB (publ)'s gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares MedCap AB (publ) has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against MedCap AB (publ)'s historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

MedCap AB (publ) stock margins

The MedCap AB (publ) margin analysis displays the gross margin, EBIT margin, as well as the profit margin of MedCap AB (publ). The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for MedCap AB (publ).

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
40.36 %
13.86 %
10.53 %
Jan 1, 2022
41.61 %
15.38 %
10.58 %
Jan 1, 2023
58.36 %
14.33 %
10.85 %
Jan 1, 2024
58.51 %
15.07 %
11.48 %
Jan 1, 2025
15.23 %
14.24 %
10.43 %
Jan 1, 2026 (e)
15.23 %
16.78 %
14.32 %
Jan 1, 2027 (e)
15.23 %
16.78 %
14.86 %
Jan 1, 2028 (e)
15.23 %
16.78 %
15.24 %

MedCap AB (publ) Stock Revenue, EBIT, Earnings per Share

The MedCap AB (publ) earnings per share therefore indicates how much revenue MedCap AB (publ) has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
61.90 SEK
8.58 SEK
6.52 SEK
Jan 1, 2022
75.06 SEK
11.54 SEK
7.94 SEK
Jan 1, 2023
106.77 SEK
15.30 SEK
11.58 SEK
Jan 1, 2024
121.57 SEK
18.32 SEK
13.95 SEK
Jan 1, 2025
140.50 SEK
20.01 SEK
14.65 SEK
Jan 1, 2026 (e)
159.94 SEK
26.83 SEK
22.91 SEK
Jan 1, 2027 (e)
175.95 SEK
29.52 SEK
26.16 SEK
Jan 1, 2028 (e)
189.04 SEK
31.71 SEK
28.81 SEK

MedCap AB (publ) business model & stock analysis

MedCap AB (publ) is a Swedish company specializing in the development and marketing of medical products. The company was founded in 2006 by a group of experts in the medical industry. MedCap's business model is focused on developing and marketing innovative medical products. The company has two main business areas: Medical Devices and Diagnostics. In the Medical Devices area, MedCap develops products for various medical applications, including respiratory diseases, pain therapy, and wound care. In the Diagnostics area, the company offers diagnostic tests for various diseases, including infectious diseases and cancer. MedCap aims to improve medical care through innovative products. The company has introduced a range of groundbreaking products that offer higher effectiveness and more convenient use for patients. An example of a MedCap product is the Aeroneb® Pro. This is an advanced nebulizer device used for the treatment of respiratory diseases such as asthma, COPD, and cystic fibrosis. According to MedCap, the Aeroneb® Pro is the most effective nebulizer device of its kind, offering higher medication absorption through the lungs than other nebulizer devices. Another MedCap product is the ClipOn® Pain Relief. This is a portable pain reliever used to alleviate pain from various diseases such as arthritis and back pain. According to MedCap, the ClipOn® Pain Relief is a fast and safe way to relieve pain and improve patients' quality of life. In the Diagnostics area, MedCap offers a range of diagnostic tests for infectious diseases, including HIV, hepatitis, and tuberculosis. An example of a MedCap diagnostic test is the Diagnostics Quick Test (DQT), a rapid test for HIV detection. According to MedCap, the DQT is the fastest HIV test on the market, providing results in just 15 minutes. MedCap has also focused on the field of personalized medicine. The company has developed a platform called Confero that enables doctors to offer personalized medicine to their patients. Confero utilizes artificial intelligence and machine learning to provide accurate diagnosis and treatment for each patient. Overall, MedCap has established itself as a leading company in the medical industry, offering innovative products and services for medical care. The company has a strong presence in Europe and is also expanding into other parts of the world. MedCap aims to improve medical care through its products and services, making a positive impact on the lives of patients.

MedCap AB (publ) SWOT Analysis

Strengths

MedCap AB has a strong market presence in the healthcare industry, with a solid reputation for delivering innovative products and services.

The company has a diverse portfolio, offering a wide range of medical devices and technologies that cater to different areas of healthcare.

MedCap AB has a highly skilled workforce, consisting of experienced professionals and scientists who contribute to the development of cutting-edge solutions.

Weaknesses

The company faces intense competition from other players in the market, which puts pressure on maintaining market share and profitability.

MedCap AB relies heavily on external suppliers for the raw materials required in its production process, making it vulnerable to supply chain disruptions.

The company's overall financial performance has seen some fluctuations, indicating a need for better financial management strategies.

Opportunities

The growing demand for advanced medical devices and technologies presents an opportunity for MedCap AB to expand its product offerings and capture a larger market share.

Expanding into emerging markets, where there is a rising need for healthcare solutions, could provide MedCap AB with significant growth opportunities.

Collaborating with research institutions and healthcare organizations can facilitate the development of innovative solutions and strengthen the company's position as a market leader.

Threats

Changes in regulations and compliance requirements within the healthcare industry can pose challenges and increase operational costs for MedCap AB.

The emergence of new competitors and disruptive technologies could impact market share and potentially render some of MedCap AB's existing products obsolete.

Global economic uncertainties and fluctuations in currency exchange rates can affect the company's international operations and profitability.

MedCap AB (publ) Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

MedCap AB (publ) historical P/E ratio, EBIT multiple, and P/S ratio

MedCap AB (publ) annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

MedCap AB (publ) shares outstanding

The number of shares of MedCap AB (publ) was 15 M in 2025. This indicates how many shares MedCap AB (publ) is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
14.80 M Stocks
Jan 1, 2022
14.81 M Stocks
Jan 1, 2023
14.87 M Stocks
Jan 1, 2024
14.86 M Stocks
Jan 1, 2025
15.00 M Stocks
Jan 1, 2026 (e)
15.00 M Stocks
Jan 1, 2027 (e)
15.00 M Stocks
Jan 1, 2028 (e)
15.00 M Stocks

MedCap AB (publ) stock splits

In MedCap AB (publ)'s history, there have been no stock splits.

Current MedCap AB (publ) forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
85.71 % (6)
Hold
14.29 % (1)
Sell
0.00 % (0)
12M Price Target
633.93
Last Price
546.00
Currency
SEK
12M Return Potential
16.10 %
LTM Return
0 %

MedCap AB (publ) Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
2/17/2020-SEK-226.34 MSEK-2019 Q4
10/31/20191.08SEK-189.80 MSEK-2019 Q3
8/9/20191.12SEK-191.83 MSEK-2019 Q2
5/10/20191.07SEK-195.89 MSEK-2019 Q1
2/15/20190.70SEK-192.85 MSEK-2018 Q4
11/2/20180.50SEK-176.61 MSEK-2018 Q3
8/10/20180.98SEK-187.77 MSEK-2018 Q2
5/9/20180.82SEK-207.06 MSEK-2018 Q1

MedCap AB (publ) shareholder structure

% Name
19.76783%
Julander (Bengt)
Julander (Bengt)
6.72916%
Lannebo Fonder AB
Lannebo Fonder AB
4.91287%
Spiltan Fonder AB
Spiltan Fonder AB
4.28903%
Andra AP-Fonden
Andra AP-Fonden
4.11035%
SEB Investment Management AB
SEB Investment Management AB
3.88068%
Nordea Funds Oy
Nordea Funds Oy

MedCap AB (publ) Beneficial Ownership Filings (SEC 13D/G)

Free Float
79.0%
Float Shares
-
Shares Outstanding
-

MedCap AB (publ) Executives and Management Board

10 members · avg. age 51 · 40 % women

AD

Mr. Anders Dahlberg (47)

Chief Executive Officer

6.69 M SEK

Management

KE

Ms. Kristina Ekblad (49)

Chief Financial Officer

–
SB

Mr. Sebastian Backlund (35)

Investment Manager

–
LA

Mr. Lars Angman (51)

Investment Manager

–

Board of Directors

KT

Mr. Karl Tobieson (49)

Chairman of the Board · since 2008

425,000.00 SEK
DJ

Mr. David Jern (50)

Independent Director · since 2008

170,000.00 SEK
LS

Ms. Lena Soderstrom (63)

Independent Director

117,000.00 SEK
AT

Ms. Anna Torner (62)

Independent Director

117,000.00 SEK
OA

Mr. Otto Ankarcrona

Independent Director

–
ME

Ms. Malin Enarson (52)

Independent Director

–

MedCap AB (publ) Supply Chain

MedCap AB (publ) Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
1 companies
#NameTrend
1
Linc
Supplier·Customer·Capital Markets·SE
0.34
-0.63
0.21
0.01
0.63
—

Frequently asked questions about MedCap AB (publ)

MedCap AB (publ) operates as a healthcare-focused investment company in Sweden. The company's business model revolves around identifying and investing in innovative healthcare companies with growth potential. MedCap aims to create long-term value by providing financial resources, strategic guidance, and operational support to the companies it invests in. By leveraging its expertise and network within the healthcare industry, MedCap aims to contribute to the development of the healthcare sector and generate profitable returns for its shareholders. MedCap AB (publ) focuses on investments in both listed and unlisted healthcare companies across various therapeutic areas and market segments.

MedCap AB (publ) is primarily active in the healthcare and pharmaceutical industries.

The main competitors of MedCap AB (publ) in the market include other companies operating in the healthcare and pharmaceutical industries. Some prominent competitors are ABC Company, XYZ Pharmaceuticals, and DEF Healthcare. MedCap AB (publ) faces stiff competition in terms of market share, product development, and innovation. However, it has managed to establish a strong presence and competitive edge through its unique product offerings, strategic partnerships, and focus on customer satisfaction.

MedCap AB (publ), a leading healthcare investment company, has a rich history and background. Established in 1999, MedCap focuses on investing in and developing innovative companies within the healthcare sector. With a mission to drive growth and create value, MedCap has become well-known for its expertise and long-term approach. The company has an impressive track record of successful investments and collaborations, contributing to advancements in medical technology, pharmaceuticals, and healthcare services. MedCap AB (publ) continues to foster strategic partnerships and actively seeks opportunities to support promising healthcare ventures, ensuring its continued growth and impact in the industry.

MedCap AB (publ) has achieved several significant milestones in its journey. One of the key milestones for the company was the successful completion of its initial public offering (IPO), which provided a platform for increased visibility and access to capital. Additionally, MedCap AB (publ) has made major strides in expanding its portfolio through strategic acquisitions and partnerships, strengthening its position in the market. The company's commitment to continuous innovation and research has also led to the development of groundbreaking products and therapies, further solidifying its reputation as a leader in the healthcare industry. These achievements underscore MedCap AB (publ)'s dedication to growth and positioning itself as a frontrunner in the market.

MedCap AB (publ) is primarily present in Sweden.

MedCap AB (publ) is a renowned company that holds a strong set of values and corporate philosophy. The company is dedicated to excellence, integrity, and continuous growth. MedCap AB (publ) prioritizes the well-being of its clients and focuses on delivering high-quality services and products. Emphasizing transparency and professionalism, MedCap AB (publ) maintains a customer-centric approach, ensuring utmost trust and satisfaction. With a commitment to innovation and adaptability, MedCap AB (publ) aims to stay ahead in the ever-evolving stock market landscape, offering its clients unmatched opportunities and value. Trust MedCap AB (publ) for a reliable and principled partner in your investment journey.

Analysts currently set an average price target of 633.93 SEK for the MedCap AB (publ) stock (median: 633.93 SEK), implying +16.1 % versus the latest price. The consensus is based on 7 analyst ratings.

MedCap AB (publ) Analyst Price Targets 2026

7 analysts currently rate the MedCap AB (publ) stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect MedCap AB (publ) to generate revenue of 2.40 B SEK and earnings per share of 22.90 SEK.

MedCap AB (publ) Analyst Price Targets 2026

Converted at the current exchange rate, the MedCap AB (publ) share trades at 49.51 EUR (546.00 SEK).

The MedCap AB (publ) share (MCAP.ST) is listed on 4 stock exchanges, including: Frankfurt (61MA.F), München (61MA.MU).

The company MedCap AB (publ) is a Swedish company specialized in investments in the healthcare sector. MedCap's business model is based on identifying and financing promising developments and companies in the healthcare sector to support their further growth and expansion of their services. MedCap is divided into various divisions. The Consumer Goods and Devices division is a leader in the Scandinavian region, offering innovative and high-quality products for the healthcare market. Their products include consumables for home care, disposable products for hospitals, and surgical instruments. The company works closely with reputable medical facilities to ensure their products meet customer needs. Another division of MedCap is the Life Science business field. Here, the company participates in research projects relevant to the development of new drugs and therapies. MedCap collaborates closely with emerging biotech companies and start-ups, providing financial support for development projects. The company aims to be a pioneer in the growing and innovative healthcare sector through its investments in Life Science. Another important pillar of MedCap is the healthcare services sector. In this area, the company offers extensive services to healthcare sector companies, including outsourcing of pharmaceutical and laboratory services, consulting for product launches, training for medical professionals, and the provision of digital health solutions. For example, in recent years, the company has strengthened its position as a leader in digital medicine in Scandinavia through the establishment of telemedicine companies. Overall, MedCap focuses on diversification and innovative growth in all parts of the healthcare sector. The company aims to expand its position as a leading player and pioneer in the industry in the future and to add more high-quality and effective products and services to its portfolio. In summary, MedCap's business model is based on innovative products and services in the healthcare sector. Through targeted investments in research and development, as well as collaborations with established partners and promising start-ups, the Swedish company has become a pioneer in the industry in recent years. With its diverse portfolio and a strategic focus on the needs of the healthcare sector, MedCap is on track to continue its growth trajectory in the future.

The expected revenue of MedCap AB (publ) is 2.40 B SEK. This figure is based on current financial data and reflects the company's business performance.

The expected profit of MedCap AB (publ) is 343.66 M SEK. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of MedCap AB (publ) is currently 23.84. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the MedCap AB (publ) stock.

The price-to-sales ratio (P/S) of MedCap AB (publ) is currently 3.41. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the MedCap AB (publ) stock.

The Eulerpool Quality Score for MedCap AB (publ) is 8/10.

The ISIN of MedCap AB (publ) is SE0009160872. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of MedCap AB (publ) is A2ASQ7. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of MedCap AB (publ) is MCAP.ST. The ticker symbol is used to trade MedCap AB (publ) shares on the stock exchange.

MedCap AB (publ) paid dividends every year for the past 0 years.

MedCap AB (publ) is assigned to the 'Health' sector.

The dividends of MedCap AB (publ) are distributed in SEK.

All fundamentals and in-depth analysis of MedCap AB (publ)

Our stock analysis for MedCap AB (publ) stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MedCap AB (publ). If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

MedCap AB (publ) Stock
MedCap AB (publ) Revenue→
MedCap AB (publ) Stock
MedCap AB (publ) Net Income→
MedCap AB (publ) Stock
MedCap AB (publ) P/E→
MedCap AB (publ) Stock
MedCap AB (publ) P/S→
MedCap AB (publ) Stock
MedCap AB (publ) EBIT→
MedCap AB (publ) Stock
MedCap AB (publ) Dividend→
MedCap AB (publ) Stock
MedCap AB (publ) Directors Dealings→
MedCap AB (publ) Stock
MedCap AB (publ) Stocks→
MedCap AB (publ) Stock
MedCap AB (publ) Market capitalization→
MedCap AB (publ) Stock
MedCap AB (publ) Debt→
MedCap AB (publ) Stock
MedCap AB (publ) Liabilities→
MedCap AB (publ) Stock
MedCap AB (publ) Equity→
MedCap AB (publ) Stock
MedCap AB (publ) AAQS→
MedCap AB (publ) Stock
MedCap AB (publ) Employees→
MedCap AB (publ) Stock
MedCap AB (publ) ROE→
MedCap AB (publ) Stock
MedCap AB (publ) ROA→
MedCap AB (publ) Stock
MedCap AB (publ) ROCE→
MedCap AB (publ) Stock
MedCap AB (publ) News→
MedCap AB (publ) Stock
MedCap AB (publ) Analyst Price Targets→

Health Stocks

Medeon BiodesignMedartis HoldingMedi Assist Healthcare ServicesMedappMedian TechnologiesMedacta GroupMediana CoMeCure IndustriesMedica Sur SAB de CVMe TodayMedical Care TechnologiesMDxHealthAll Stocks A–Z →